Market Call: Gordon Reid's outlook on U.S. Equities (April 23, 2026)

Key Concepts

• Forward-Looking Markets: The principle that markets price in resolutions to geopolitical events quickly, leading to "V-shaped" recoveries.
• Productivity Spike: The theory that AI implementation is beginning to drive record corporate profit margins and efficiency.
• Patent Cliff: The phenomenon where pharmaceutical companies face revenue declines as major drugs lose patent protection, necessitating a robust pipeline of new drugs.
• Capital Expenditure (CapEx) Digestion: The process of investors evaluating whether massive AI-related spending will yield adequate returns.
• Net Interest Income: The difference between interest earned on loans and interest paid on deposits, a key driver for bank profitability.
• GLP-1 Technology: A class of drugs used for diabetes and obesity treatment, representing a significant growth sector in pharmaceuticals.

---

Market Outlook and Macro Perspective

Gordon Reid emphasizes that market volatility driven by geopolitical events (such as conflicts in the Middle East) is typically temporary. He argues that markets are forward-looking and expect resolutions, which prevents structural economic damage. Regarding AI, Reid notes that while initial spending caused investor nervousness, we are now seeing the "beginnings of the effects of AI" through record corporate profit margins and a new productivity cycle. He advises investors to "defend against the bad and embrace the good."

Sector Analysis

1. Technology and AI

• Alphabet (Google): Reid remains bullish, describing it as a "bigger pie" story. Despite search market share potentially declining from the mid-90s, the total addressable market is expanding. He highlights YouTube’s dominance (23% share) and Waymo (self-driving) as key pillars.
• Meta: Trading at a reasonable multiple (~21x earnings), Meta is viewed as a strong investment. Reid defends their massive CapEx ($115B–$130B projected) as a necessary investment in AI that will generate future cash flow.
• Apple: Reid views Apple’s AI strategy as consistent with their historical model: letting others innovate and spend, then entering the market with vast resources once the technology is commercially viable.
• Microsoft: Considered a stable participant in the AI space with a strong cloud presence (Azure) and a significant stake in OpenAI.

2. Pharmaceuticals

• Merck: Viewed as a constructive "pure pharma" play with a deep pipeline of Phase 2 and 3 drugs to offset the upcoming "patent cliff" of their oncology drug, Keytruda.
• Amgen: Favored for its double-digit revenue growth across 15 mature compounds.
• Novo Nordisk vs. Eli Lilly: Reid prefers Eli Lilly, noting that Novo Nordisk is losing market share in the obesity drug race. He anticipates a shift toward oral delivery systems for GLP-1 drugs in the near future.

3. Financials

• Bank of America & Morgan Stanley: Reid favors these for their exposure to net interest income and capital markets. He notes that Morgan Stanley’s recent report, showing a 27% return on tangible common equity, was exceptional.
• Citigroup: Identified as an "up and coming" value play undergoing a renaissance under CEO Jane Fraser.
• Private Credit: Reid clarifies that recent bank volatility was a liquidity and sales issue rather than a fundamental credit failure.

4. Retail and Consumer Goods

• Lululemon: Reid is skeptical due to cultural and management issues, noting the stock's significant decline. He suggests alternatives like Gildan (which is integrating the Hanes brand) and PVH (Calvin Klein/Tommy Hilfiger).
• Nike: Avoided due to ongoing turnaround struggles and lack of demonstrated execution.

---

Step-by-Step Investment Framework

Reid’s methodology for evaluating companies includes:

1. Cash Flow Analysis: Prioritizing companies that fund AI and growth initiatives through free cash flow rather than excessive debt.
2. Management Execution: Assessing leadership's ability to pivot (e.g., GM’s move away from pure EV focus to match consumer demand).
3. Valuation Discipline: Avoiding "dead money" (stocks already priced for a takeover) and seeking companies trading at reasonable multiples (e.g., 7x earnings for GM).
4. Portfolio Construction: Avoiding ETFs in favor of picking specific "haves" within a sector to maximize returns.

---

New Top Picks

• GATX: A railcar leasing company that recently doubled its fleet size through a joint venture with Brookfield Infrastructure. It is seen as a stable, quality play with a 12% ROE.
• General Motors (GM): Favored for its disciplined execution and pivot away from aggressive EV targets to align with current consumer demand. Trading at ~7x earnings.
• McKesson: The world’s largest pharmaceutical distributor. Reid highlights its stability, aging demographic tailwinds, and role in distributing GLP-1 drugs.

---

Synthesis

Gordon Reid’s core thesis is that investors should focus on high-quality, cash-generative companies that are successfully navigating the transition to an AI-driven economy. He warns against "greed" and over-enthusiasm, advocating for a balanced approach where investors own a "basket" of strong companies rather than betting on single-name turnarounds. His outlook remains cautiously optimistic, emphasizing that while geopolitical headlines create noise, the underlying fundamentals of well-managed corporations remain robust.